Mesoblast (NASDAQ: MESO) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Mesoblast to related businesses based on the strength of its earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Mesoblast and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mesoblast $2.41 million -$76.81 million -6.90
Mesoblast Competitors $217.29 million -$39.39 million -79.10

Mesoblast’s rivals have higher revenue and earnings than Mesoblast. Mesoblast is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Mesoblast and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mesoblast -2,006.86% -12.04% -9.60%
Mesoblast Competitors -3,150.94% -535.47% -40.46%

Risk & Volatility

Mesoblast has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Comparatively, Mesoblast’s rivals have a beta of 1.57, suggesting that their average stock price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Mesoblast and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast 0 2 4 0 2.67
Mesoblast Competitors 535 2425 6647 126 2.65

Mesoblast presently has a consensus target price of $14.25, indicating a potential upside of 164.87%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 20.69%. Given Mesoblast’s stronger consensus rating and higher probable upside, equities analysts plainly believe Mesoblast is more favorable than its rivals.

Insider and Institutional Ownership

2.9% of Mesoblast shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mesoblast Company Profile

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.